DEA OKs Mass THC Production for Isotope Lab Testing Needs
Published Date: 9/24/2026
Notice
Summary
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Applicant to Make THC Analytical Standards
On August 19, 2026, Cambridge Isotope Laboratories applied to be registered to bulk manufacture Tetrahydro-cannabinols (drug code 7370), a Schedule I controlled substance. The company plans to synthetically bulk manufacture the substance to produce analytical standards for distribution to its customers.
Registration Limited to Analytical Standards Only
The notice states that no other activity for drug code 7370 is authorized for this registration. If granted, the registration would authorize only the synthetic bulk manufacture of Tetrahydro-cannabinols to produce analytical standards for distribution to customers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19542, Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company
Cayman Chemical Company wants to become an official bulk maker of some powerful controlled substances, mostly in Schedule I. This means they’ll be able to produce these drugs in large amounts for research or medical use. If you have thoughts or objections, you’ve got until November 23, 2026, to speak up online—no fees or money changes yet, just a chance to weigh in!
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
2026-19400, Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I
The Drug Enforcement Administration wants to put five specific hallucinogenic drugs into Schedule I, meaning they’ll be treated as illegal with strict rules. This affects anyone who makes, sells, studies, or owns these drugs, adding serious legal consequences. You have until October 23, 2026, to share your thoughts or ask for a hearing before the rule might become official.
Previous / Next Documents
Previous: 2026-19536, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Federal Direct PLUS Loan Request for Supplemental Information
The Department of Education wants to update the form for Federal Direct PLUS Loan applicants to collect extra info. This affects parents and grad students applying for these loans and aims to make the process smoother and clearer. Comments on the changes are open until October 26, 2026, with no new fees involved.
Next: 2026-19539, Importer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to become an official importer of certain controlled substances, including Gamma Hydroxybutyric Acid and Tetrahydrocannabinols. People and companies involved with these drugs can comment or ask for a hearing by October 26, 2026. This move could impact how these substances are imported and regulated, but no direct costs are mentioned yet.